AQR Capital Management
XFOR icon

AQR Capital Management’s X4 Pharmaceuticals XFOR Stock Holding History

AQR Capital Management’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-26,382
Closed -$50.1K – 3609
2025
Q2 		$50.1K Buy
26,382
+23,483
+810% +$96.1K ﹤0.01% 3237
2025
Q1 		$20.6K Buy
2,899
+2,004
+224% +$27.6K ﹤0.01% 3126
2024
Q4 		$19.7K Sell
895
-22,962
-96% -$366K ﹤0.01% 2847
2024
Q3 		$479K Buy
23,857
+9,722
+69% +$203K ﹤0.01% 2193
2024
Q2 		$246K Buy
14,135
+12,937
+1,080% +$423K ﹤0.01% 2346
2024
Q1 		$49.9K Sell
1,198
-4,280
-78% -$119K ﹤0.01% 2375
2023
Q4 		$138K Buy
5,478
+3,435
+168% +$83.5K ﹤0.01% 2256
2023
Q3 		$66.8K Buy
+2,043
New +$89.1K ﹤0.01% 2268

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AQR Capital Management's XFOR Position: Q3 2025 in Review

AQR Capital Management sold out of X4 Pharmaceuticals (XFOR) in Q3 2025, closing a stake of 26,382 shares — an estimated $50.1K sold.

AQR Capital Management first reported a position in XFOR in Q3 2023 and held it in 8 quarters. The position peaked at $479K in Q3 2024. 42 funds tracked by Wall St. Rank hold XFOR as of Q3 2025.

  • AQR Capital Management reported no remaining X4 Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • AQR Capital Management sold 26,382 X4 Pharmaceuticals shares in Q3 2025, an estimated $50.1K.
  • AQR Capital Management first reported a position in X4 Pharmaceuticals in Q3 2023 and held it in 8 quarters.
  • AQR Capital Management's X4 Pharmaceuticals position peaked at $479K in Q3 2024.
  • 42 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q3 2025.

Based on AQR Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.